BioCardia Receives Two New U.S. Patents
BioCardia, Inc. (BCDA)
US:NASDAQ Investor Relations:
biocardia.com/investors/press-releases/id/1037?pressreleaseid=41
Company Research
Source: PR Newswire
SAN CARLOS, Calif., Sept. 14, 2018 /PRNewswire/ -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of two United States patents. U.S. Patent No. 10,035,982 relates to methods of preparing culture-expanded cells for the treatment of heart failure. The patent has broad claims on an approach for expanding mesenchymal stem cells in media derived from the blood of the same donor who has provided the source cells for culture expansion. In the patented method, a single donor provides the source cells for expansion of the targeted stem cells and blood over time to produce a donor-specific culture medium. The claimed method may provide a solution to the risks and potential immune reactions associated with cells manufactured utilizing culture media derived from animal and human sources.As the second issued patent, U.S. Patent No. 10,071,226 describes a system for delivery of biotherape
Show less
Read more
Impact Snapshot
Event Time:
BCDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCDA alerts
High impacting BioCardia, Inc. news events
Weekly update
A roundup of the hottest topics
BCDA
News
- BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)GlobeNewswire
- BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the HeartGlobeNewswire
- BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)GlobeNewswire
- BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDAGlobeNewswire
BCDA
Sec Filings
- 3/3/26 - Form 8-K
- 2/10/26 - Form 8-K
- 2/4/26 - Form 4
- BCDA's page on the SEC website